| Name | Title | Contact Details |
|---|---|---|
Coe Salzgeber |
Senior Director, Data & Infrastructure | Profile |
Lisa Hall |
Chief Information Security Officer | Profile |
Alamar Biosciences is a biotechnology company that has developed a next generation proteomic platform with ultra high sensitivity and multiplexing capability for plasma protein detection and liquid biopsies.
With offices in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies. The Company`s first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company is preparing for clinical trials in the U.S. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.
MOBILion Systems is enabling advancements in disease diagnosis and treatment by commercializing instruments that improve multi-omics disease, drug, and biomarker discovery.
Nurix Therapeutics discovers drugs that harness the body`s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
Medarray is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.